RHU ORGANOMIC

Fascinating insights into cancer research! Fanny Jaulin, PhD and her team are exploring how cancer cells move collectively to form metastases, a process known as "collective invasion." Their work focuses on understanding and slowing this mechanism, particularly in colorectal cancer. This groundbreaking research is featured in the second episode of the Institut national du cancer's immersive podcast "Parlons recherche contre les cancers". 🎧 A must-listen to learn more about the incredible people driving progress in oncology. #CancerResearch #Innovation #CollectiveInvasion #Oncology

Thrilled to see Alice Boilève featured! As a clinical fellow in medical oncology at Gustave Roussy, Alice has been instrumental in advancing our RHU project. Her dedication enabled the ORGANOTREAT-01 trial to move forward, driving impactful research on PDAC and CRC cancers. Kudos to Alice for her hard work and outstanding contributions! 👏🎥 #Oncology #Research #Innovation

👏

We are delighted to announce that 𝟭𝟬 𝗻𝗲𝘄 𝘀𝘁𝗮𝗿𝘁-𝘂𝗽𝘀 𝗵𝗮𝘃𝗲 𝗯𝗲𝗲𝗻 𝘀𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗯𝘆 𝘁𝗵𝗲 𝗣𝗮𝗿𝗶𝘀 𝗦𝗮𝗰𝗹𝗮𝘆 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗹𝘂𝘀𝘁𝗲𝗿 (𝗣𝗦𝗖𝗖) to join its bustling community and benefit from a world-class ecosystem, bringing the total number of cutting-edge projects supported by the oncocluster to 60. 🚀 𝗦𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗳𝗼𝗿 𝘁𝗵𝗲𝗶𝗿 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀, these start-ups are driving innovation in biotechnology, diagnostics, and therapeutics, paving the way for the future of oncology.   ➡️ DeepLife: A biotech company using cutting-edge multi-omics data, AI, and systems engineering to identify molecular triggers that restore diseased cells to a healthy state. ➡️ Minos Biosciences: A start-up bridging molecular and cell biology like never before, providing unparalleled insights into cell diversity and dynamics. ➡️ ORINOVA Therapeutics: Developing gold nanoparticles engineered to deliver anti-tumoral drugs for glioblastoma treatment. ➡️ OncoNext-Remunity: A clinical-stage biopharma advancing next-generation immunotherapeutics to combat cancer. ➡️ Odimma Therapeutics: Creating personalized immunotherapies using AI and synthetic DNA technology. ➡️ see2cure: Innovating a diagnostic probe for fluorescence-guided surgery, enabling precise tumor visualization and reducing relapse risks in abdominal cancers. ➡️ Stimunity: Developing mRNA-based therapies to stimulate innate immunity through the cGAS pathway. ➡️ Curenetics: Offering an AI-powered tool to help patients and doctors make informed decisions on optimal cancer treatments. ➡️ ReACT Therapeutics: Developing BCPR inhibitors to enhance the efficacy of cancer treatments. ➡️ Yomi Pharma: Harnessing the natural properties of sortilin protein to target EGFR-positive tumors with innovative therapies.   With these new additions, the PSCC remains at the forefront of fostering innovation, providing expertise, infrastructure, networking, and resources to accelerate breakthroughs in the fight against cancer. 🌟 Are you developing an innovative solution for patients in oncology? Come and join us: https://lnkd.in/dw8KsGT5 #Innovation #Oncology #PSCC #HealthcareInnovation #Biotechnology

#GivingTuesday : on a tous un rôle à jouer contre le #cancer ! 💙 Partout dans le monde, nous célébrons aujourd'hui la Journée mondiale de la générosité et de la solidarité. ✨ Votre générosité nous est précieuse pour parvenir plus vite à #GuérirLeCancerAu21eSiècle : vos dons sont essentiels pour soutenir les équipes de Gustave Roussy dans leur lutte quotidienne contre le cancer. Rejoignez le mouvement #GivingTuesday aux côtés de l'institut 👉 https://lnkd.in/evnkbdrZ

🚀  Orakl Oncology is thrilled to announce a seed round of €11 million to launch first-in-class AI-powered drug development products for biopharma and biotech ✨ We raised €11 million in seed funding, led by Singular. This investment follows a €3M pre-seed round in October 2023 led by Speedinvest with participation from HCVC and Verve Ventures. This funding will fuel the development of Orakl’s business unit and prepare the company for strategic collaborations with pharmaceutical partners. To lead this initiative, we have appointed Jessica Atkinson (FMI, Merck) as Business Advisor and opened a BD director position. We are now marketing our first AI-powered commercial solutions, the first product, O-Predict, forecasts patient responses to new drug candidates, predicting key clinical outcomes such as the number of responders and progression-free survival. 🔮 Our mission at Orakl is to revolutionize drug development by offering an unparalleled decision-making platform that empowers drug developers to de-risk clinical trials and expedite the availability of new transformative medicines. We aim to redefine the future of precision medicine and deliver breakthroughs that patients desperately need. 🙏 We warmly thank our investors and business angels for their continuous support in this mission, as well as Gustave Roussy, our other partners, and our Oraklees for their tremendous contributions. We will be recruiting, stay posted! SISTAFUND, Tatiana Jama Natacha Brami, Jonathan Benhamou, Sébastien Bazin, Paul Bazin, Maximilien Levesque, Mostafa ElSayed, François Morice, Bpifrance Thanks to Les Echos and TechCrunch for their articles about Orakl Oncology, you will find the links in the comment section. cc Fanny Jaulin, PhD, Diane-Laure Pagès, Gustave Ronteix, Jeremy Uzan, Maud Larbey, Andrea Zitna, Estelle Botbol 🎗️, Alexis Houssou, Xavier Mesnier, Fabrice Barlesi, Christophe Javaud

💥I’m thrilled to share that I had the privilege of writing the scientific proposal that secured €1.5 million in funding for a groundbreaking project at Okomera. 🧬This initiative combines the transformative power of CRISPR-Cas9 with Okomera’s cutting-edge organoid screening technology to create an advanced target validation and identification platform directly on patient-derived organoids (PDOs)—miniaturized models that more accurately represent human diseases. 💊 This platform will pave the way for breakthroughs in drug discovery and precision medicine by enhancing our ability to study cancer mechanisms, validate therapeutic targets, and identify new ones. 🤝 Collaborating with esteemed researchers like Dr. Thomas Miller (IPC/CRCM - Centre de Recherche en Cancérologie de Marseille) and Dr. Geraldine Guasch (Inserm/CRCM - Centre de Recherche en Cancérologie de Marseille), this effort reflects the power of combining cutting-edge technologies with scientific expertise. 🌟 A heartfelt thanks to Bpifrance for recognizing the potential of this work and awarding this substantial grant. 💬 Let’s connect! I’d love to exchange insights on innovation, research, and the future of drug discovery. #Innovation #CancerResearch #CRISPR #Organoids #DrugDiscovery #TargetValidation #TargetIdentification #Collaboration

🇯🇵 Come and meet Orakl Oncology at our booth during Hello Tomorrow Japan Deep Tech Summit 2024 in Tokyo this Friday Diane-Laure Pagès, co-founder and COO, will be in Tokyo from Dec 2nd to Dec 6th for both Hello Tomorrow Japan Deept Tech Summit and Innovation Leaders Summit, ''Asia's largest open innovation event'' to meet Japanese and international partners, and present how we transform and accelerate drug development in oncology with our unique patient tumor avatars. Thanks to J. D. F. and Diane D. from Hello Tomorrow Japan for the invitation and coordination! #deeptech #tokyo #innovation #drugdevelopment #oncology

📢 Exciting News Today ! We’re thrilled to share that Fanny Jaulin, PhD, our Scientific Coordinator, has been invited to speak today at the 20th Annual Meeting of the Canceropole GSO, taking place at the Congress Center in Perpignan. This prestigious event is a cornerstone for researchers and clinicians in the Greater South-West of France, offering a unique opportunity to discuss cutting-edge programs and strategic priorities in cancer research. It also fosters collaboration across scientific communities, paving the way for impactful partnerships and innovative projects. We’re proud to see our work represented at such a key gathering and look forward to the fruitful exchanges it will inspire. 🌟 #CancerResearch #Collaboration #Innovation

✨️Greatful for the bright and sharp-witted PhD students of the consortium who are sharing their amazing work internationally ! 💪Well done Emmanouil Angelidakis #cancerresearch